<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1d3 20150301//EN"  "JATS-archivearticle1.dtd"><article article-type="research-article" dtd-version="1.1d3" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">61119</article-id><article-id pub-id-type="doi">10.7554/eLife.61119</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Cell Biology</subject></subj-group><subj-group subj-group-type="heading"><subject>Neuroscience</subject></subj-group></article-categories><title-group><article-title>Burst mitofusin activation reverses neuromuscular dysfunction in murine CMT2A</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-198508"><name><surname>Franco</surname><given-names>Antonietta</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-5487-1800</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="par-5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-198509"><name><surname>Dang</surname><given-names>Xiawei</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-0343-7107</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-198510"><name><surname>Walton</surname><given-names>Emily K</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-198511"><name><surname>Ho</surname><given-names>Joshua N</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-116244"><name><surname>Zablocka</surname><given-names>Barbara</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-2204-5184</contrib-id><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-198512"><name><surname>Ly</surname><given-names>Cindy</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-195370"><name><surname>Miller</surname><given-names>Timothy M</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-135539"><name><surname>Baloh</surname><given-names>Robert H</given-names></name><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-169144"><name><surname>Shy</surname><given-names>Michael E</given-names></name><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-59726"><name><surname>Yoo</surname><given-names>Andrew S</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-0304-3247</contrib-id><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-197979"><name><surname>Dorn II</surname><given-names>Gerald W</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-8995-1624</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="cor1">*</xref><xref ref-type="other" rid="par-1"/><xref ref-type="other" rid="par-2"/><xref ref-type="other" rid="par-3"/><xref ref-type="other" rid="par-4"/><xref ref-type="other" rid="par-6"/><xref ref-type="fn" rid="conf2"/></contrib><aff id="aff1"><institution content-type="dept">Department of Internal Medicine, Pharmacogenomics</institution>, <institution>Washington University School of Medicine</institution>, <addr-line><named-content content-type="city">St Louis</named-content></addr-line>, <country>United States</country></aff><aff id="aff2"><institution content-type="dept">Department of Developmental Biology</institution>, <institution>Washington University School of Medicine</institution>, <addr-line><named-content content-type="city">St Louis</named-content></addr-line>, <country>United States</country></aff><aff id="aff3"><institution content-type="dept">Molecular Biology Unit</institution>, <institution>Mossakowski Medical Research Centre</institution>, <addr-line><named-content content-type="city">Warsaw</named-content></addr-line>, <country>Poland</country></aff><aff id="aff4"><institution content-type="dept">Department of Neurology</institution>, <institution>Washington University School of Medicine</institution>, <addr-line><named-content content-type="city">St Louis</named-content></addr-line>, <country>United States</country></aff><aff id="aff5"><institution content-type="dept">Department of Neurology</institution>, <institution>Cedars-Sinai Medical Center</institution>, <addr-line><named-content content-type="city">Los Angeles</named-content></addr-line>, <country>United States</country></aff><aff id="aff6"><institution content-type="dept">Department of Neurology</institution>, <institution>Carver College of Medicine, University of Iowa</institution>, <addr-line><named-content content-type="city">Iowa City</named-content></addr-line>, <country>United States</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor" id="author-18694"><name><surname>Gleeson</surname><given-names>Joseph G</given-names></name><role>Reviewing editor</role><aff><institution>Howard Hughes Medical Institute, The Rockefeller University</institution>, <country>United States</country></aff></contrib></contrib-group><author-notes><corresp id="cor1"><label>*</label>For correspondence: <email>gdorn@wustl.edu</email> (GD);</corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>19</day><month>10</month><year>2020</year></pub-date><volume>9</volume><elocation-id>e61119</elocation-id><history><date date-type="received"><day>15</day><month>07</month><year>2020</year></date><date date-type="accepted"><day>18</day><month>10</month><year>2020</year></date></history><permissions><copyright-statement>Â© 2020, Franco et al</copyright-statement><copyright-year>2020</copyright-year><copyright-holder>Franco et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link> permitting unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-61119-v1.pdf"/><abstract><p>Charcot-Marie-Tooth disease type 2A (CMT2A) is an untreatable childhood peripheral neuropathy caused by mutations of the mitochondrial fusion protein, mitofusin (MFN) 2. Here, pharmacological activation of endogenous normal mitofusins overcame dominant inhibitory effects of CMT2A mutants in reprogrammed human patient motor neurons, reversing hallmark mitochondrial stasis and fragmentation independent of causal <italic>MFN2</italic> mutation. In mice expressing human <italic>MFN2</italic> T105M, intermittent mitofusin activation with a small molecule, MiM111, normalized CMT2A neuromuscular dysfunction, reversed pre-treatment axon and skeletal myocyte atrophy, and enhanced axon regrowth by increasing mitochondrial transport within peripheral axons and promoting <italic>in vivo</italic> mitochondrial localization to neuromuscular junctional synapses. MiM111-treated <italic>MFN2</italic> T105M mouse neurons exhibited accelerated primary outgrowth and greater post-axotomy regrowth, linked to enhanced mitochondrial motility. MiM111 is the first pre-clinical candidate for CMT2A.</p></abstract><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Mouse</kwd></kwd-group><funding-group><award-group id="par-1"><funding-source><institution-wrap><institution>NIH</institution></institution-wrap></funding-source><award-id>R35HL135736</award-id><principal-award-recipient><name><surname>Dorn II</surname><given-names>Gerald W</given-names></name></principal-award-recipient></award-group><award-group id="par-2"><funding-source><institution-wrap><institution>NIH</institution></institution-wrap></funding-source><award-id>R41NS113642</award-id><principal-award-recipient><name><surname>Dorn II</surname><given-names>Gerald W</given-names></name></principal-award-recipient></award-group><award-group id="par-3"><funding-source><institution-wrap><institution>NIH</institution></institution-wrap></funding-source><award-id>R41NS115184</award-id><principal-award-recipient><name><surname>Dorn II</surname><given-names>Gerald W</given-names></name></principal-award-recipient></award-group><award-group id="par-4"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100005202</institution-id><institution>Muscular Dystrophy Association</institution></institution-wrap></funding-source><award-id>628906</award-id><principal-award-recipient><name><surname>Dorn II</surname><given-names>Gerald W</given-names></name></principal-award-recipient></award-group><award-group id="par-5"><funding-source><institution-wrap><institution>McDonnell Center for Cellular and Molecular</institution></institution-wrap></funding-source><award-id>Neurobiology Postdoctoral Fellowship</award-id><principal-award-recipient><name><surname>Franco</surname><given-names>Antonietta</given-names></name></principal-award-recipient></award-group><award-group id="par-6"><funding-source><institution-wrap><institution>Harrington Discovery Institute</institution></institution-wrap></funding-source><award-id>Scholar-Innovator awardee</award-id><principal-award-recipient><name><surname>Dorn II</surname><given-names>Gerald W</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group></article-meta></front><back><sec id="s1" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interest</title><fn fn-type="conflict" id="conf2"><p>Gerald W Dorn II, G.W.D. is an inventor on patent applications PCT/US18/028514 submitted by Washington University and PCT/US19/46356 submitted by Mitochondria Emotion, Inc that cover the use of small molecule mitofusin agonists to treat chronic neurodegenerative diseases, and is a founder of Mitochondria in Motion, Inc., a Saint Louis based biotech R&amp;D company focused on enhancing mitochondrial trafficking and fitness in neurodegenerative diseases..</p></fn><fn fn-type="conflict" id="conf1"><p>The other authors declare that no competing interests exist.</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>Animal experimentation: All experimental procedures were approved by Washington University in St. Louis School of Medicine Animal Studies Committee; IACUC protocol number 19-0910, Exp:12/16/2022 (Gerald Dorn, PI).</p></fn></fn-group></sec><sec id="s2" sec-type="supplementary-material"><title>Additional Files</title><sec id="s3" sec-type="data-availability"><title>Data availability</title><p>All data generated or analyzed during this study are included in the manuscript.</p></sec><supplementary-material><ext-link xlink:href="elife-61119-supp-v1.zip">Download zip</ext-link><p>Any figures and tables for this article are included in the PDF. The zip folder contains additional supplemental files.</p></supplementary-material></sec></back></article>